Deltagen Presents At Bio-Life-Tech 2010 Conference
09 12월 2010 - 2:00AM
Business Wire
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug
discovery tools to the biopharmaceutical industry, today presented
an overview of Deltagen's business, including its Benten
Bioservices (“Benten”) opportunity, at the Bio-Life-Tech 2010
conference in Baltimore, Maryland. A slide deck summarizing the
presentation has been posted on the Company’s website at
www.deltagen.com.
Deltagen's cash is expected to be sufficient to support the
purchase of initial capital equipment and the build-out of Benten's
Malvern, Pennsylvania facility. Deltagen is seeking funds to
support its Benten operations through profitability and to position
the Company for future growth. There can be no assurance that
Deltagen will be successful in raising these funds or that Benten
will reach profitability. This release is not an offer to sell, nor
the solicitation of an offer to buy, securities.
About Deltagen
Deltagen, Inc. is a leading provider of drug discovery tools to
the biopharmaceutical industry. Deltagen offers access to its
extensive inventory of knockout mouse lines and related phenotypic
data, which enhance the efficiency of target validation and drug
discovery. In addition, Deltagen offers target validation data in
the areas of immunology and metabolic diseases. Deltagen's products
and programs have been validated by customers and partners such as
Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Inc. and
Pfizer Inc. Benten BioServices, Inc. (“Benten”), a wholly-owned
subsidiary of Deltagen based in Malvern, Pennsylvania, will provide
regulatory-compliant services to support the development and
commercialization of biopharmaceutical products. Benten’s services
are designed to address specific requirements for critical stages
in product development, including biosafety testing, raw materials
testing, assay and process validation services, cell banking and
characterization services, and technology platform-specific R&D
support and consulting services. For more information on Deltagen,
visit the Company's website at www.deltagen.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements about Deltagen's future revenues, cash flows
and operating results, Benten's business plans, as well as other
matters that are not historical facts or information. These
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Deltagen's ability to achieve its operational objectives and
revenue projections, that may cause Deltagen's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. There are no assurances that
the Company will be able to fulfill its financial obligations,
obtain sufficient additional cash to fund its Benten operations,
succeed in pursuing its business plan, or achieve profitability or
future growth consistent with its current projections. Information
identifying such important risk factors is contained in the
Company's most recent "Management's Discussion and Analysis of
Financial Conditions and Results of Operations", which can be found
at Deltagen's website at www.deltagen.com. Deltagen undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
Deltaagen (CE) (USOTC:DGEN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Deltaagen (CE) (USOTC:DGEN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
